ORLANDO, Fla., May 22, 2013 (GLOBE NEWSWIRE) -- A groundbreaking animal study by renowned researcher, surgeon and gastroenterologist, Professor Roman M. Herman, M.D. of the Jagiellonian University Medical College, Krakow, Poland has won the prestigious Poster of Distinction Award at the Digestive Disease Week meeting in Orlando, Florida. Professor Herman's animal research, using the Secca® protocol in a porcine model of fecal incontinence examined how non-ablative radiofrequency energy (RF) remodels anal sphincter muscle tissue.
The study demonstrated that:
- RF significantly influenced internal (IAS) and external (EAS) anal sphincter structure and composition, improving muscle contraction
- In the IAS, RF increased the number and diameter of smooth muscle fibers
- Collagen 1 tissue increased while collagen 3 decreased
- RF reduced the number and distribution of Interstitial Cells of Cajal, responsible for IAS relaxation
"Our previous clinical study, funded by a Polish Ministry of Science Grant, proved fecal incontinence can be successfully treated with the Secca procedure, a non-ablative RF treatment," said principal investigator Professor Herman. "The study demonstrated improvements in patient symptoms and quality of life as well as improvement in motility without any evidence of stricture or fibrosis. This was confirmed by anorectal manometry, electromyography and other physiological studies.
"The animal study helps us understand the physiological changes we see in patients and how RF works at the cellular level – and provides better understanding of diseases that affect the muscles in the digestive tract," Herman said.
It is estimated that one in 13 adults suffer from fecal incontinence –including one in 3 women who have given birth. Unfortunately only 20 percent of these patients ever talk to their doctor about these issues.
"This data goes a long way in explaining how RF works when applied at controlled low temperatures to smooth muscle. The studies reinforce the clinical outcomes and physiological changes," said Will Rutan, CEO of Mederi Therapeutics. "As we expand our clinical data, we can cite very specific mechanisms of action of our RF treatment – and these will drive clinical use."
About Mederi Therapeutics
Greenwich, Connecticut-based Mederi Therapeutics manufactures and markets innovative medical devices that deliver low power, low temperature radiofrequency energy (RF) to treat digestive diseases. The recently released second generation technology, Stretta for GERD and Secca for Bowel Incontinence, featuring enhancements in safety and ease of use, are non-surgical outpatient treatments that deliver RF to the sphincters at either end of the digestive system. These therapies bridge the gap between conservative therapy and invasive surgery or implants – offering effective, less complicated, and less costly alternatives. Stretta and Secca provide durable relief to symptoms and are strongly backed by numerous clinical studies showing safety and long-term effectiveness. Products are available in North America, South America, Europe, the Middle East and Asia.
CONTACT: Edna Kaplan firstname.lastname@example.org 617-974-8659/mobileSource: Mederi Therapeutics